---
layout: default
title: Nitrogen
parent: Model Prediction Only (L5)
nav_order: 344
evidence_level: L5
indication_count: 10
---

# Nitrogen
{: .fs-9 }

Evidence Level: **L5** | Predicted Indications: **10** 
{: .fs-6 .fw-300 }

---

## Table of Contents
{: .no_toc .text-delta }

1. TOC
{:toc}

---

<div id="pharmacist">

## Pharmacist Assessment Report

</div>

# Nitrogen: From Congenital Alveolar Capillary Dysplasia to 16q24.1 Microdeletion Syndrome

## One-Sentence Summary

Nitrogen is used in inhaled nitric oxide gas mixtures (as a diluent or carrier gas). Its original indications are congenital alveolar capillary dysplasia and persistent fetal circulation syndrome.
The TxGNN model predicts it may be effective for **16q24.1 microdeletion syndrome**, but **no clinical trials and no relevant publications** support this prediction.

## Quick Overview

| Item | Content |
|------|------|
| Original Indication | Congenital alveolar capillary dysplasia; persistent fetal circulation syndrome (taken from the knowledge graph, as the SAHPRA registrations list no approved indication text) |
| Predicted New Indication | 16q24.1 microdeletion syndrome |
| TxGNN Prediction Score | 99.73% |
| Evidence Level | L5 |
| South Africa Market Status | Marketed |
| Number of SAHPRA Registrations | 2 |
| Recommended Decision | Hold |

## Why is This Prediction Reasonable?

Detailed mechanism of action data is not available for this drug. Nitrogen is an inert gas, and in this setting it serves as a diluent or carrier for inhaled nitric oxide mixtures rather than as an active agent.

The prediction arises from the knowledge graph. The 16q24.1 deletion involves *FOXF1* and neighbouring regulatory elements, the same locus implicated in congenital alveolar capillary dysplasia, the drug's original indication. The shared genetic and disease-network neighbours explain the high score.

This link is a knowledge-graph artefact, not a therapeutic mechanism. Nitrogen has no pharmacological activity on the underlying genetic defect, so the prediction should not be read as a treatment signal.

The other top predictions follow the same pattern: childhood interstitial lung disease, isolated pulmonary capillaritis, congenital pulmonary lymphangiectasia, Dandy-Walker malformation syndrome, hair shaft abnormalities and hypertrichosis. Each is driven by disease similarity or shared genetic neighbours, with no pharmacological rationale.

## Clinical Trial Evidence

Currently no related clinical trials registered.

## Literature Evidence

Currently no related literature available for the leading prediction (16q24.1 microdeletion syndrome).

Searches for lower-ranked predictions returned only keyword-level matches. Examples are nitric oxide and nitrosative stress studies and toxicology studies for benign adrenal neoplasm, periodontal and oral microbiome papers for the odontal malformation syndrome, and cyclosporin A and de Lange syndrome papers for hypertrichosis. These evaluate nitrogen-containing compounds or unrelated topics, not nitrogen gas as a treatment, so they provide no therapeutic evidence.

## South Africa Market Information

| Registration Number | Product Name | Dosage Form | Approved Indication |
|---------|------|------|-----------|
| Exclusion under Section 36 & Section 14 | ITN paediatric TPN 107 | TPN | Not stated |
| Article 21B (N/A) | TPN non-specific | Infusion | Not stated |

Both registrations are single-ingredient entries with valid status. Essential Medicines List status could not be confirmed from the data compiled for this report.

## Safety Considerations

- **Knowledge-graph contraindications** (not from label text): methemoglobinemia, sulfhemoglobinemia and heart failure.
- **Drug interactions**: none found in the interaction query.

Please refer to the SAHPRA-approved Professional Information (PI) for full warnings and contraindications. Report adverse drug reactions to SAHPRA.

## Conclusion and Next Steps

**Decision: Hold**

**Rationale:**
The prediction rests only on model scores and knowledge-graph proximity. There are no clinical trials, no relevant literature and no plausible pharmacological mechanism for an inert gas in 16q24.1 microdeletion syndrome. The evidence level is L5.

**To proceed, the following is needed:**
- Retrieval of SAHPRA package insert warnings and contraindications (a blocking gap for safety screening)
- Mechanism of action data from DrugBank
- Any direct clinical or mechanistic evidence for a therapeutic role in the predicted indication; without it, this candidate should not advance beyond the current stage
## Disclaimer

This content is for research purposes only and does not constitute medical advice.
Clinical validation is required before any clinical application.

---

